WO2007110667A1 - Piperidines and related compounds for the treatment of dementia - Google Patents
Piperidines and related compounds for the treatment of dementia Download PDFInfo
- Publication number
- WO2007110667A1 WO2007110667A1 PCT/GB2007/050155 GB2007050155W WO2007110667A1 WO 2007110667 A1 WO2007110667 A1 WO 2007110667A1 GB 2007050155 W GB2007050155 W GB 2007050155W WO 2007110667 A1 WO2007110667 A1 WO 2007110667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- compounds
- compound according
- methyl
- bond
- Prior art date
Links
- 0 *C(CC=O)(CC(*c1ccccc1)=O)C(O*)=O Chemical compound *C(CC=O)(CC(*c1ccccc1)=O)C(O*)=O 0.000 description 4
- OEYJLSDPHSHAPQ-UHFFFAOYSA-O COC(Cc1cc(-c2ccc(C(F)(F)F)cc2)ncc1)=[OH+] Chemical compound COC(Cc1cc(-c2ccc(C(F)(F)F)cc2)ncc1)=[OH+] OEYJLSDPHSHAPQ-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- This invention relates to compounds for use in therapeutic treatment of the human body.
- it provides carboxy- functional 1 ,2-disubstituted piperidines and related compounds useful for treating diseases associated with the deposition of ⁇ -amyloid peptide in the brain, such as Alzheimer's disease, or of preventing or delaying the onset of dementia associated with such diseases.
- AD Alzheimer's disease
- DSM-IV American Psychiatric Association
- a ⁇ fibrillar aggregates of ⁇ -amyloid peptide
- a ⁇ is formed from amyloid precursor protein (APP) via separate intracellular proteolytic events involving the enzymes ⁇ -secretase and ⁇ -secretase.
- APP amyloid precursor protein
- a ⁇ of varying chain length e.g. A ⁇ (l-38), A ⁇ (l-40) and A ⁇ (l-42).
- N-terminal truncations such as A ⁇ (4-42) are also found in the brain, possibly as a result of variability in the site of proteolysis mediated by ⁇ -secretase.
- expressions such as "A ⁇ (l-40)” and “A ⁇ (l-42)" as used herein are inclusive of such N- terminal truncated variants.
- a ⁇ After secretion into the extracellular medium, A ⁇ forms initially-soluble aggregates which are widely believed to be the key neurotoxic agents in AD (see Gong et al, PNAS, 100 (2003), 10417-22), and which ultimately result in the insoluble deposits and dense neuritic plaques which are the pathological characteristics of AD.
- dementing conditions associated with deposition of A ⁇ in the brain include cerebral amyloid angiopathy, hereditary cerebral haemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
- Other proposed methods of treatment include administering a compound which blocks the aggregation of A ⁇ , and administering an antibody which selectively binds to A ⁇ .
- Another proposed treatment is that of modulation of the action of ⁇ -secretase so as to selectively attenuate the production of A ⁇ (l-42). This results in preferential secretion of the shorter chain isoforms of A ⁇ , which are believed to have a reduced propensity for self-aggregation and plaque formation, and hence are more easily cleared from the brain, and/or are less neurotoxic.
- Compounds showing this effect include certain non-steroidal antiinflammatory drugs (NSAIDs) and their analogues (see WO 01/78721 and US 2002/0128319 and Weggen et al Nature, 414 (2001) 212-16; Morihara et al, J. Neurochem., 83 (2002), 1009-12; and Takahashi et al, J.
- V represents a bond or a carbon atom whose remaining valencies are satisfied via bonding to H, R or X-Z or to any combination thereof;
- W represents a nitrogen atom or a carbon atom whose remaining valencies are satisfied via bonding to H, R 2 or X-Z or to any combination thereof, provided that when W represents a nitrogen atom, V represents a carbon atom and the moiety X-Z is attached to W;
- X represents a bond or C(R') 2 or CH 2 C(R') 2 , provided that when W represents N, X does not represent a bond;
- Y represents a bond or CH 2 or CH 2 CH 2 ;
- Z represents CO 2 H or a tetrazole ring;
- each R 1 independently represents H or a non-aromatic hydrocarbon group of up to 6 carbon atoms; or the two R 1 groups complete a C3_6alicyclic group;
- R 2 represents a non-aromatic hydrocarbon group of up to 6 carbon atoms
- R 3 and R 4 each represents H, or when V and W each represents a carbon atom, R 3 and R 4 may together represent a CH 2 CH 2 bridge
- each R 5 independently represents halogen, bearing 0-3 fluorine substituents, bearing 0-3 fluorine substituents, or C 2 -6alkenyl
- R 6 represents Het-A- where A represents a bond, CH 2 or 1 ,4-phenylene and Het represents a heterocyclic ring system of up to 10 ring atoms which optionally bears up to 3 substituents selected from halogen, and or which optionally bears a phenyl substituent which itself is optionally substituted with halogen, and
- R 7 represents a hydrocarbon group of up to 10 carbon atoms which optionally bears a CF 3 substituent.
- variable occurs more than once in formula I
- identity taken by said variable at any particular occurrence is independent of the identity taken at any other occurrence.
- hydrocarbon group refers to groups consisting solely of carbon and hydrogen atoms. Unless indicated otherwise, such groups may comprise linear, branched or cyclic structures, singly or in any combination consistent with the indicated maximum number of carbon atoms, which may be saturated or unsaturated, including aromatic.
- carbon group refers to groups consisting solely of carbon and hydrogen atoms. Unless indicated otherwise, such groups may comprise linear, branched or cyclic structures, singly or in any combination consistent with the indicated maximum number of carbon atoms, which may be saturated or unsaturated, including aromatic.
- the expression “Ci_ x alkyl” where x is an integer greater than 1 refers to straight- chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
- C 2 - 6 alkenyl such as "C 2 - 6 alkenyl”, “hydroxyCi. 6 alkyl”, “heteroarylCi. 6 alkyl”, “C 2 - 6 alkynyl” and “Ci_ 6 alkoxy” are to be construed in an analogous manner.
- C 3 _6alicyclic refers to cyclic non-aromatic hydrocarbon groups containing from 3 to 6 ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentenyl, cyclopentyl and cyclohexyl.
- heterocyclic refers to mono- or bicyclic ring systems in which at least one ring atom is selected from N, O and S. Unless indicated otherwise, the term includes both saturated and unsaturated systems, including aromatic systems. Heterocyclic groups may be bonded via a ring carbon or a ring nitrogen, unless otherwise indicated.
- halogen as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred unless otherwise indicated.
- the compounds of formula I may be in the form of pharmaceutically acceptable salts.
- Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tart
- a pharmaceutically acceptable salt may be formed by neutralisation of the carboxylic acid group with a suitable base.
- suitable base examples include alkali metal salts such as sodium or potassium salts; ammonium salts; alkaline earth metal salts - A -
- salts formed with suitable organic bases such as amine salts (including pyridinium salts) and quaternary ammonium salts.
- V represents a bond or a carbon atom and W represents a nitrogen atom or a carbon atom, with the proviso that when W represents a nitrogen atom, V cannot be a bond and the moiety X-Z must be attached to W.
- Formula I therefore encompasses pyrrolidine, piperidine and piperazine derivatives, depending on the identities of V and W.
- V represents a carbon atom, and hence completes a piperidine or piperazine ring.
- the moiety X-Z may be attached at any available ring position, including ring positions represented by V and W, but when W represents a nitrogen atom, X-Z must be attached to W.
- X-Z is not attached at either of the positions adjacent to the nitrogen atom which is bonded to the moiety - CHR 6 R 7 .
- X-Z is typically attached at the 3-, 4- or 5- position, preferably the 3- or 4-position, and most preferably at the 4-position.
- the nitrogen atom of the piperidine ring shall be taken as the 1 -position, and the carbon atom bonded to Y and R 4 as the 2-position.
- Z represents CO 2 H or a tetrazole ring, in particular, Z represents CO 2 H or l,2,3,4-tetrazol-5-yl, but preferably represents CO 2 H.
- the group X represents a bond, C(R') 2 or CH 2 C(R') 2 , where each R 1 independently represents H or a non-aromatic hydrocarbon group of up to 6 carbon atoms; or the two R 1 groups complete a C3.
- ⁇ alicyclic group such as cyclopropyl, cyclobutyl, cyclopentenyl or cyclopentyl.
- one R 1 group is H and the other is H or such as methyl, ethyl, propyl or butyl.
- X include a bond, CH 2 , CH(CH 3 ), CH 2 CH 2 , cyclopentan-l,l-diyl and cyclopent-3-en-l,l-diyl, with the proviso that when W represents a nitrogen atom, X cannot be a bond.
- X represents a bond or CH 2
- most preferably X represents CH 2 .
- Y represents a bond, CH 2 or CH 2 CH 2 , preferably a bond or CH 2 , and most preferably a bond.
- the group R (when present) may be attached at any available position on the ring, including a carbon atom represented by V or W and including a carbon atom to which the moiety X-Z is attached.
- p is 0 and R is absent.
- p is 1
- V and W complete a piperidine ring and R 2 and the moiety X-Z are both attached at the 4-position thereof.
- p is 1, V and W complete a piperidine ring, R is attached at the 3 -position and the moiety X-Z is attached at the 4-position.
- R 3 and R 4 each represent H, or when V and W each represents a carbon atom, R 3 and R 4 may together represent -CH 2 CH 2 -, thereby completing a bridged bicyclic structure.
- p is preferably 0, and Y is preferably a bond.
- R 3 and R 4 both represent H.
- q is preferably 1 or 2, most preferably 1.
- Each R 5 independently represents halogen (especially F), bearing 0-3 fluorine substituents, bearing 0-3 fluorine substituents or C 2 _ 6 alkenyl. When one R 5 is present, it is very suitably (but not necessarily) attached in the 4-position.
- Typical identities for (R 5 ) q include 2-CF 3 , 3-CF 3 , 4-CF 3 , 2,4-di(CF 3 ), 2-F-4-CF 3 , 4-OCF 3 , 4-allyl, 4-n- propyl, 4-isopropyl and 4-tert-butyl.
- (R 5 ) q represents 4-CF 3 or 4-n-propyl, in particular 4-CF 3 .
- R 6 represents Het-A where A represents a bond, CH 2 or 1 ,4-phenylene, and Het represents a heterocyclic system of up to 10 ring atoms which is optionally substituted as defined previously.
- Het represents a 5- or 6-membered heterocycle which optionally is fused to a second 5- or 6-membered ring.
- Said second 5- or 6-membered ring may be carbocyclic or heterocyclic, and when Het represents a group comprising a heterocyclic ring fused to a carbocyclic ring, attachment to the remainder of the molecule may be via either of these rings.
- Any ring comprised by the group represented by Het may be saturated or unsaturated, including aromatic.
- heterocyclic systems within the definition of Het include pyridine, quinoline, isoquinoline, furan, benzofuran, thiophene, benzothiophene, pyrazole, triazole, tetrahydropyran, tetrahydrothiopyran, piperidine and tetrahydrofuran.
- the group Het may be unsubstituted or substituted as defined previously.
- Preferred substituents include CF 3 (especially methyl), (such as t-butoxycarbonyl), phenyl and trifluoromethylphenyl.
- A represents 1 ,4-phenylene
- Het typically represents a monocyclic system which does not bear a phenyl or substituted phenyl substituent.
- groups represented by R 6 include: 3-pyridyl, 6-trifluoromethyl-3-pyridyl, 2-furyl, 5-
- R 7 represents a hydrocarbon group of up to 10 carbon atoms optionally bearing a CF 3 substituent.
- Said hydrocarbon group may be fully saturated or may comprise one or more double or triple bonds or combinations thereof, and may include a phenyl ring.
- said hydrocarbon group contains up to 8 carbon atoms, e.g. up to 6 carbon atoms.
- Typical hydrocarbon groups include alkyl (in particualr branched alkyl), alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, phenyl and phenylalkyl of up to 10 carbon atoms, e.g. up to 8 carbon atoms, and in particular up to 6 carbon atoms in total.
- R 7 represents an unsubstituted hydrocarbon group.
- unsubstituted hydrocarbon groups represented by R 7 include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, 3-methylbutyl, 2-ethylbutyl, 4-methylpentyl, 3,3-dimethylbutyl, 3-methylbuten-l-yl, 3-methylbut-3-en-l-ynyl, 4-methylpent-l-ynyl, 3,3- dimethylbut-1-ynyl, cyclohexyl, phenyl, cyclopropylmethyl, cyclohexylethynyl, benzyl and 2-phenylethyl.
- R 7 bears a CF 3 substituent.
- substituted hydrocarbon groups represented by R 7 include 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 1-methyl- 3,3,3-trifluoropopyl, and 4-trifluoromethylphenyl.
- a first subset of the compounds according to the invention consists of the compounds of formula II:
- a second subset of the compounds according to the invention consists of the compounds of formula III:
- Y is preferably a bond
- p is preferably O.
- a third subset of the compounds according to the invention consists of the compounds of formula IV:
- R a represents H, halogen or CF 3 ; and R 6 and R 7 have the same definitions and preferred identities as before.
- the substituted phenyl group attached to the 2-position of the piperidine ring and the CH 2 CO 2 H group attached in the 4-position are advantageously (but not necessarily) in the czs-configuration with respect to the piperidine ring.
- R a represents H
- R represents d. 6 alkyl such as methyl or ethyl and p, q, V, W, X, Y, R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the same meanings as before, e.g. by refluxing with LiOH in aqueous THF.
- Corresponding compounds in which Z represents lH-tetrazol-5-yl are obtainable by conversion of the esters (1) to the corresponding nitriles, followed by treatment with azidotrimethylsilane in refluxing toluene in the presence of tributyltin oxide.
- the conversion to the nitrile may be carried out by adding trimethylaluminium to a suspension of ammonium chloride in toluene, then adding the ester (1), refluxing the mixture, and treating with solid potassium sodium tartrate.
- Compounds (1) may be obtained by reaction of compounds (2) with R 6 R 7 CH-L:
- L is a leaving group such as halide (especially bromide or iodide), tosylate, mesylate or triflate, and
- R, p, q, V, W, X, Y, R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the same meanings as before.
- Normal alkylating conditions may be employed, e.g. heating in DMF solution in the presence of base such as potassium carbonate.
- compounds (2) may undergo reductive alkylation with precursors of the group
- R 6 R 7 CH- which contain an aldehyde or ketone functionality.
- the compound (2) may be refluxed with R 6 -CO-R 7 in toluene in the presence of an acid catalyst, with azeotropic removal of water, and the resulting adduct reduced using sodium triacetoxyborohydride.
- R 7 is an alkyn-1-yl group
- a compound (2) is reacted with R 6 -CHO and R 7 -H in the presence of gold(III) bromide, e.g. via microwave heating at 7O 0 C in water.
- the compound (2), R 6 -CHO and benzotriazole are refluxed in toluene with azeotropic removal of water, and the resulting adduct reacted with R 7 -Zn-Hal where Hal represents halide (preferably chloride) and R 6 and R 7 have the same meanings as before.
- the reaction is suitably carried out in an anhydrous aprotic solvent such as dichloromethane at reduced temperature, e.g. below 1O 0 C.
- Piperidines (2) in which V and W are both carbon atoms and R 3 and R 4 are H may be obtained by hydrogenation of the corresponding pyridines (3):
- R, p, q, X, Y, R 2 and R 5 have the same meanings as before, e.g. in methanolic HCl over a Pt ⁇ 2 catalyst.
- Pyridines (3) in which X is a bond and Y is CH 2 are obtainable by coupling of chloropyridines (4a) with benzylzinc derivatives (5b).
- the reaction may be carried out at O 0 C to ambient temperature in THF in the presence of a nickel catalyst such as (Ph 3 P) 2 NiCl 2 .
- Pyridines (3) in which X is a bond and Y is CH 2 CH 2 are obtainable by coupling of chloropyridines (4a) with alkynes (5c) followed by hydrogenation.
- the coupling may be carried out in the presence of CuI and a Pd(O) catalyst such as Pd(Ph 3 ) 4 , e.g. in a mixture of dioxan and triethylamine with microwave heating.
- the hydrogenation takes place under similar conditions to the conversion of pyridines (3) to piperidines (2), and indeed is preferably combined with that process.
- Pyridines (3) in which X is CH 2 may be obtained by elaboration of chloropyridines (4b) with (5a), (5b) or (5c) as described above, then treating the product with CO(OR) 2 in the presence of strong base such as lithium diisopropylamide, where R has the same meaning as before.
- the chloropyridines (4b) may be treated with CO(OR) 2 prior to the reaction with (5a), (5b) or (5c).
- Piperidines of formula (2) in which V and W are both carbon atoms and R 3 and R 4 are H, X is a bond, p is 1 and R 2 is attached to the same ring position as the CO 2 R group are obtained by alkylation of the corresponding compounds in which p is 0 with R -L, where L has the same meaning as before.
- the reaction may be carried out in THF solution in the presence of strong base such as lithium hexamethyldisilazide (HMDS). During this procedure, it is preferable to protect the 1 -position of the piperidine ring, e.g. as the BOC derivative.
- HMDS lithium hexamethyldisilazide
- esters (1) in which V and W are both carbon atoms and R 3 and R 4 are H, p is 0, X is CH 2 and the CH 2 CO 2 R group is attached to the 4-position involves condensation of piperidones
- Ketones (6) are available by reduction of dihydropyridones (8):
- piperidones( ⁇ ) may be obtained in a one-pot process by reacting the aforesaid imines with trimethyl[(l-methyleneprop-2-en-l-yl)oxy]silane (e.g. in dichloromethane at ambient temperature under an inert atmosphere), then adding tetrabutylammonium fluoride.
- Y is preferably a bond.
- the above-described routes involving dihydropyridines (8) or (10) may be adapted to provide products having an R 2 in the 3-position of the piperidine ring via alkylation of the compounds (8) or (10) with R -L, where R and L have the same meanings as before. Said alkylation takes place under conventional conditions (e.g. in THF in the presence of lithium diisopropylamide).
- the aforesaid routes may be adapted to provide products having an R group in the 6- position of the piperidine ring via treatment of compounds (8) or (10) with R 2 -Mg-halide in the presence of CuI, where R has the same meaning as before.
- the reaction may be carried out in THF at reduced temperature (e.g. -78 0 C to -1O 0 C).
- the aforesaid routes may be adapted to provide products in which the -CH 2 CO 2 R group is attached at the 3 -position of the piperidine ring via alkylation of compounds (8) or (10) with L-CH 2 CO 2 R, where L and R have the same meanings as before, followed by reduction of the keto group to CH 2 .
- the alkylation takes place under conventional conditions, and reduction of the keto group is readily effected via treatment with 1,2-ethanedithiol to form the dithioketal, followed by treatment with Raney nickel.
- R, Y, q, R 5 , R 6 and R 7 have the same meanings as before.
- the cyclisation takes place in the presence of a Ru catalyst and the reduction may be effected by treatment with Mg in methanol.
- Dienes (12) are obtainable by alkylation of secondary amines (13) with the appropriate bromomethacrylate ester, and amines (13) are available by condensation of aldehydes (9) with R 6 R 7 CH-NH 2 and treatment of the product with allyltributylstannane:
- R, Y, q, R 5 , R 6 and R 7 have the same meanings as before.
- the reaction may be carried out by heating at about 16O 0 C with sodium chloride in DMSO. Subsequent reflux of the product with sodium methoxide in methanol causes epimerisation at the 4-position and enrichment with the czs-isomer at the expense of the trans-isomer.
- Bis-esters (14) are available from the reaction of amines R 6 R 7 CH-NH 2 with diketones (15):
- the first step may be carried out in dimethoxyethane in the presence of a tertiary amine and TiCLt at -78 0 C with warming to ambient.
- the second step may be carried out by adding a methanolic solution of sodium cyanoborohydride to the reaction mixture at room temperature.
- Diketones (15) may be obtained by alkylation of the appropriate allylmalonate dialkyl ester with a compound of formula (16):
- the alkylation may be carried out in DMF in the presence of NaH (e.g. at ambient temperature).
- the ozonolysis may be effected by passing ozone-enriched oxygen through a dichloromethane solution of the substrate at -78 0 C, adding dimethyl sulfide, then stirring overnight at ambient temperature.
- Piperidines of formula (2) in which R 3 and R 4 complete a -CH 2 CH 2 - bridge and Y is a bond may be obtained by elaboration of bicyclic ketones (17):
- the bicyclic ketones (17) are available by reaction of 4-methoxybenzylamine with acetonedicarboxylic acid, then treatment of the product in situ with a ketoaldehyde (18):
- R 5 and q have the same meanings as before.
- a preferred route to piperazines of formula (1) in which V is a carbon atom and W is a nitrogen atom involves alkylation of compounds (19) with L-X'-CC ⁇ R:
- Compounds (20) using the methods described previously for conversion of compounds (2) to compounds (1), followed by removal of the trityl group (e.g. by treatment with methanolic HCl).
- Compounds (20) are available via coupling of compounds(5a), (5b) or (5c) with the appropriate pyrazine derivatives in the manner described above for the synthesis of pyridines (3), followed by hydrogenation (as in the conversion of compounds (3) to compounds (2)) and tritylation by standard methods.
- a preferred route to pyrrolidines of formula (1) in which V is a bond, p is 0 and X represents CH 2 involves the steps of (a) condensing an aldehyde (9) with t-butylsulphinamide and reacting the resulting imine with ally IMgBr to provide the adduct (21a):
- a piperidine of formula (2a), an aldehyde R 6 -CHO and a 1-alkyne are subjected to microwave heating in the presence of go Id(III) bromide (e.g. at about 7O 0 C), providing compounds of formula IV in which R 7 is 1 -alkynyl.
- go Id(III) bromide e.g. at about 7O 0 C
- the corresponding compounds in which R 7 is alkyl or alkenyl may be obtained by hydrogenation of the alkynyl derivatives (e.g. in ethyl acetate over a Pd/C catalyst).
- Carboxylic acids of formula I in which X is a bond may be converted to the corresponding compounds in which X is CH 2 by standard methods of homologation, for example sequential treatment with oxalyl chloride; trimethylsilyldiazomethane and acetonitrile; ROH and silver benzoate; then hydrolysis of the resulting ester. Similar treatment of the corresponding compounds in which X is CH 2 provides the compounds in which X is CH 2 CH 2 .
- Esters of formula (1) in which X is C(R') 2 or CH 2 C(R') 2 and at least one R 1 is other than H may be prepared by alkylation of the corresponding compounds in which each R 1 is H by standard methods.
- a given compound in accordance with formula I may be converted to a different compound in accordance with formula I by means of the standard techniques of bond formation or cleavage known to those skilled in the art of organic synthesis.
- Certain compounds according to the invention may exist as optical isomers due to the presence of one or more chiral centres or because of the overall asymmetry of the molecule. Such compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as di-p-toluoyl-D-tartaric acid and/or di-p-toluoyl-L-tartaric acid, followed by fractional crystallisation and regeneration of the free base.
- the novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
- racemic intermediates in the preparation of compounds of formula I may be resolved by the aforementioned techniques, and the desired enantiomer used in subsequent steps.
- racemic piperidine derivatives (2a) may be resolved via salt formation with L- mandelic acid.
- any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T. W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3 rd ed., 1999.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- the compounds of the invention have the useful property of modifying the action of ⁇ -secretase on amyloid precursor protein so as to selectively reduce the formation of the 1-42 isoform of A ⁇ , and hence find use in the development of treatments for diseases mediated by A ⁇ (l-42), in particular diseases involving deposition of ⁇ -amyloid in the brain.
- the disease associated with deposition of A ⁇ in the brain is typically Alzheimer's disease (AD), cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome, preferably AD.
- AD Alzheimer's disease
- HCHWA-D cerebral amyloid angiopathy
- multi-infarct dementia dementia pugilistica or Down syndrome
- the invention provides the use of a compound of Formula I as defined above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating, preventing or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome.
- the invention also provides a method of treating or preventing a disease associated with deposition of A ⁇ in the brain comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I as defined above or a pharmaceutically acceptable salt thereof.
- the invention provides a method of treating, preventing or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I as defined above or a pharmaceutically acceptable salt thereof.
- the compounds of Formula I modulate the action of ⁇ -secretase so as to selectively attenuate production of the (1-42) isoform of A ⁇ without significantly lowering production of the shorter chain isoforms such as A ⁇ (l-40). This results in secretion of A ⁇ which has less tendency to self-aggregate and form insoluble deposits, is more easily cleared from the brain, and/or is less neurotoxic. Therefore, a further aspect of the invention provides a method for retarding, arresting or preventing the accumulation of A ⁇ in the brain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I as defined above or a pharmaceutically acceptable salt thereof.
- the compounds of formula I modulate the activity of ⁇ -secretase, as opposed to suppressing said activity, it is believed that the therapeutic benefits described above will be obtained with a reduced risk of side effects, e.g. those that might arise from a disruption of other signalling pathways (e.g. Notch) which are controlled by ⁇ -secretase.
- the compound of Formula I is administered to a patient suffering from AD, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome, preferably AD.
- the compound of Formula I is administered to a patient suffering from mild cognitive impairment or age-related cognitive decline.
- a favourable outcome of such treatment is prevention or delay of the onset of AD.
- Age-related cognitive decline and mild cognitive impairment (MCI) are conditions in which a memory deficit is present, but other diagnostic criteria for dementia are absent (Santacruz and Swagerty, American Family Physician, 63 (2001), 703-13). (See also "The ICD-IO Classification of Mental and Behavioural Disorders", Geneva: World Health Organization, 1992, 64-5).
- age-related cognitive decline implies a decline of at least six months' duration in at least one of: memory and learning; attention and concentration; thinking; language; and visuospatial functioning and a score of more than one standard deviation below the norm on standardized neuropsychologic testing such as the MMSE. In particular, there may be a progressive decline in memory. In the more severe condition MCI, the degree of memory impairment is outside the range considered normal for the age of the patient but AD is not present.
- the differential diagnosis of MCI and mild AD is described by Petersen et ah, Arch. Neurol, 56 (1999), 303-8. Further information on the differential diagnosis of MCI is provided by Knopman et al, Mayo Clinic Proceedings, 78 (2003), 1290-1308. In a study of elderly subjects, Tuokko et al (Arch, Neurol., 60 (2003) 577-82) found that those exhibiting MCI at the outset had a three- fold increased risk of developing dementia within 5 years.
- the compound of Formula I is advantageously administered to patients who suffer impaired memory function but do not exhibit symptoms of dementia.
- impairment of memory function typically is not attributable to systemic or cerebral disease, such as stroke or metabolic disorders caused by pituitary dysfunction.
- Such patients may be in particular people aged 55 or over, especially people aged 60 or over, and preferably people aged 65 or over.
- Such patients may have normal patterns and levels of growth hormone secretion for their age. However, such patients may possess one or more additional risk factors for developing Alzheimer's disease.
- Such factors include a family history of the disease; a genetic predisposition to the disease; elevated serum cholesterol; and adult-onset diabetes mellitus.
- the compound of Formula I is administered to a patient suffering from age-related cognitive decline or MCI who additionally possesses one or more risk factors for developing AD selected from: a family history of the disease; a genetic predisposition to the disease; elevated serum cholesterol; adult-onset diabetes mellitus; elevated baseline hippocampal volume; elevated CSF levels of total tau; elevated CSF levels of phospho-tau; and lowered CSF levels of A ⁇ (l-42),
- a genetic predisposition (especially towards early onset AD) can arise from point mutations in one or more of a number of genes, including the APP, presenilin-1 and presenilin-2 genes.
- subjects who are homozygous for the ⁇ 4 isoform of the apolipoprotein E gene are at greater risk of developing AD.
- the patient's degree of cognitive decline or impairment is advantageously assessed at regular intervals before, during and/or after a course of treatment in accordance with the invention, so that changes therein may be detected, e.g. the slowing or halting of cognitive decline.
- a variety of neuropsychological tests are known in the art for this purpose, such as the Mini-Mental State Examination (MMSE) with norms adjusted for age and education (Folstein et al., J. Psych.
- MMSE Mini-Mental State Examination
- the MMSE is a brief, quantitative measure of cognitive status in adults. It can be used to screen for cognitive decline or impairment, to estimate the severity of cognitive decline or impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment.
- ADAS Alzheimer Disease Assessment Scale
- ADAS-COg cognitive element thereof
- Rosen et al., Am. J. Psychiatry, 141 (1984), 1356-64 Another suitable test is the Alzheimer Disease Assessment Scale (ADAS), in particular the cognitive element thereof (ADAS-COg) (See Rosen et al., Am. J. Psychiatry, 141 (1984), 1356-64).
- the compounds of Formula I are typically used in the form of pharmaceutical compositions comprising one or more compounds of Formula I and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the principal active ingredient typically is mixed with a pharmaceutical carrier, e.g.
- a tableting ingredient such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate and dicalcium phosphate, or gums, dispersing agents, suspending agents or surfactants such as sorbitan monooleate and polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a homogeneous preformulation composition containing a compound of the present invention, or a pharmaceutically acceptable salt thereof.
- these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient.
- Tablets or pills of the composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(ethylene glycol), poly(vinylpyrrolidone) or gelatin.
- a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and more preferably about 0.05 to 50 mg/kg of body weight per day, of the active compound.
- the compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, a dosage outside these limits may be used.
- the compounds of Formula I optionally may be administered in combination with one or more additional compounds known to be useful in the treatment or prevention of AD or the symptoms thereof.
- additional compounds thus include cognition-enhancing drugs such as acetylcholinesterase inhibitors (e.g. donepezil and galanthamine), NMDA antagonists (e.g. memantine) or PDE4 inhibitors (e.g. ArifloTM and the classes of compounds disclosed in WO 03/018579, WO 01/46151, WO 02/074726 and WO 02/098878).
- additional compounds also include cholesterol-lowering drugs such as the statins, e.g. simvastatin.
- Such additional compounds similarly include compounds known to modify the production or processing of A ⁇ in the brain ("amyloid modifiers"), such as compounds which inhibit the secretion of A ⁇ (including ⁇ -secretase inhibitors, ⁇ -secretase inhibitors, and GSK-30C inhibitors), compounds which inhibit the aggregation of A ⁇ , and antibodies which selectively bind to A ⁇ .
- amloid modifiers compounds which inhibit the secretion of A ⁇ (including ⁇ -secretase inhibitors, ⁇ -secretase inhibitors, and GSK-30C inhibitors), compounds which inhibit the aggregation of A ⁇ , and antibodies which selectively bind to A ⁇ .
- growth hormone secretagogues as disclosed in WO 2004/110443.
- the amyloid modifier may be a compound which inhibits the secretion of A ⁇ , for example an inhibitor of ⁇ -secretase (such as those disclosed in WO 01/90084, WO 02/30912, WO 01/70677, WO 03/013506, WO 02/36555, WO 03/093252, WO 03/093264, WO 03/093251, WO 03/093253, WO 2004/039800, WO 2004/039370, WO 2005/030731, WO 2005/014553, WO 2004/089911, WO 02/081435, WO 02/081433, WO 03/018543, WO 2004/031137, WO 2004/031139, WO 2004/031138, WO 2004/101538, WO 2004/101539 and WO 02/47671.), or a ⁇ - secretase inhibitor (such as those disclosed in WO 03/037325, WO 03/030886,
- amyloid modifier is advantageously a ⁇ -secretase inhibitor, preferred examples of which include a compound of formula XI:
- m is 0 or 1
- X is Cl or CF 3
- Y is OH, OCi. ⁇ alkyl, NH 2 or NHCi_ 6 alkyl.
- Particular examples include those in which m is 1 and Y is OH (or the sodium salts thereof), and those in which m is 0 and Y is NH 2 or
- ⁇ -secretase inhibitors for use in this embodiment of the invention is that defined by formula XII:
- X is very aptly 5-substituted-thiazol-2-yl, 5-substituted-4-methylthiazol-2-yl, 5-substituted-l- methylpyrazol-3-yl, 1 -substituted-imidazol-4-yl or 1 -substituted- 1,2,4-triazo 1-3 -yl.
- R represents optionally-substituted phenyl or heteroaryl such as phenyl, monohalophenyl, dihalophenyl, trihalophenyl, cyanophenyl, methylphenyl, methoxyphenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, pyridyl, monohalopyridyl and trifluoromethylpyridyl, wherein "halo" refers to fluoro or chloro.
- R-X- Particularly preferred identities of R-X- include 5-(4-fluorophenyl)-l-methylpyrazol-3-yl, 5-(4- chlorophenyl)-l -methylpyrazol-3-yl and l-(4-fluorophenyl)imidazol-4-yl.
- Such compounds may be prepared by methods disclosed in WO 03/093252.
- the amyloid modifier may be a compound which inhibits the aggregation of A ⁇ .
- suitable examples include chelating agents such as clioquinol (Gouras and Beal, Neuron, 30 (2001), 641- 2) and the compounds disclosed in WO 99/16741, in particular that known as DP- 109 (Kalendarev et al, J. Pharm. Biomed. Anal., 24 (2001), 967-75).
- inhibitors of A ⁇ aggregation suitable for use in the invention include the compounds disclosed in WO 96/28471, WO 98/08868 and WO 00/052048, including the compound known as ApanTM (Praecis); WO 00/064420, WO 03/017994, WO 99/59571 and the compound known as AlzhemedTM (Neurochem); WO 00/149281 and the compositions known as PTI-777 and PTI-00703 (ProteoTech); WO 96/39834, WO 01/83425, WO 01/55093, WO 00/76988, WO 00/76987, WO 00/76969, WO 00/76489, WO 97/26919, WO 97/16194, and WO 97/16191.
- the amyloid modifier may be an antibody which binds selectively to A ⁇ .
- Said antibody may be polyclonal or monoclonal, but is preferably monoclonal, and is preferably human or humanized.
- the antibody is capable of sequestering soluble A ⁇ from biological fluids, as described in WO 03/016466, WO 03/016467, WO 03/015691 and WO 01/62801.
- Suitable antibodies include humanized antibody 266 (described in WO 01/62801) and the modified version thereof described in WO 03/016466.
- the expression "in combination with” requires that therapeutically effective amounts of both the compound of Formula I and the additional compound are administered to the subject, but places no restriction on the manner in which this is achieved.
- the two species may be combined in a single dosage form for simultaneous administration to the subject, or may be provided in separate dosage forms for simultaneous or sequential administration to the subject. Sequential administration may be close in time or remote in time, e.g. one species administered in the morning and the other in the evening.
- the separate species may be administered at the same frequency or at different frequencies, e.g. one species once a day and the other two or more times a day.
- the separate species may be administered by the same route or by different routes, e.g. one species orally and the other parenterally, although oral administration of both species is preferred, where possible.
- the additional compound is an antibody, it will typically be administered parenterally and separately from the compound of Formula I.
- the invention provides the combination of a compound of formula I or a pharmaceutically acceptable salt thereof and a compound of formula XI(a) or a pharmaceutically acceptable salt thereof for use in treatment or prevention of a disease associated with deposition of ⁇ - amyloid in the brain. Said use may involve the simultaneous or separate administration of the respective compounds to a patient in need of such treatment or prevention.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula I or a pharmaceutically acceptable salt thereof and a compound of formula XI(a) or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition is in a unit dose form suitable for oral administration, such as a tablet or a capsule.
- Human SH-SY5Y neuroblastoma cells overexpressing the direct ⁇ -secretase substrate SPA4CT were induced with sodium butyrate (10 mM) for 4 hours prior to plating.
- Cells were plated at 35,000 cells/well/100 ⁇ l in 96-well plates in phenol red-free MEM/10% FBS, 50 mM HEPES, 1% Glutamine and incubated for 2 hrs at 37 0 C, 5% CO 2 .
- a ⁇ (42) premix 0.5 ⁇ g/ml ruthenylated G2-11 antibody, 4 ⁇ g/ml biotinylated 4G8 antibody diluted in Origen buffer
- LD 50 and IC 5 O values for inhibition of A ⁇ (40) and A ⁇ (42) were calculated by nonlinear regression fit analysis using the appropriate software (eg. Excel fit). The total signal and the background were defined by the corresponding Me 2 SO and inhibitor controls.
- the free base was obtained by treatment with NaHCO 3 (aq) and extraction in to DCM.
- the organic extracts were dried, filtered and evaporated.
- Step 2 ( ⁇ ) Methyl ⁇ (25'*,4 ⁇ *)-l- ⁇ (l ⁇ *)-4-methyl-l-[6-(trifluoromethyl)pyridin-3-yl]pent-4-en-2-yn-l- yl ⁇ -2-[4-(trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetate
- Step 3 ( ⁇ ) ⁇ (2S*,4R *)-l- ⁇ (lR *)-4-methyl-l-[6-(trifluoromethyl)pyridin-3-yl]pent-4-en-2-yn-l-yl ⁇ -2- [4-(trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetic acid
- Step 2 ⁇ (25',4 ⁇ )-l-[(l ⁇ )-4-methyl-l-(tetrahydro-2H-pyran-4-ylmethyl)pentyl]-2-[4- (trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetic acid
- Step 1 ( ⁇ ) Methyl ⁇ (2R*, 4S*)-l-[(lS*)-4-methyl-l-(4-pyridin-4-ylphenyl)pentyl]-2-[4- (trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetate
- Step 2 ( ⁇ ) ⁇ (2R*, 4S*)-l-[(lS*)-4-methyl-l-(4-pyridin-4-ylphenyl)pentyl]-2-[4- (trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetic acid
- CD 3 OD ⁇ 0.64-0.72 (IH, m), 0.74-0.79 (IH, m), 0.85-0.87 (6H, m), 1.50 (IH, septet, J 6.6), 1.64 (IH, q, J 12.4), 1.95 (IH, q, J 12), 2.15-2.24 (3H, m), 2.28-2.41 (4H, m), 3.49 (IH, dt, J 2.5, 12.7), 3.72 (IH, d, J 12.1), 4.06 (IH, dd, J 2.5, 12.4), 4.96 (IH, dd, J 2.2, 11.5), 7.56 (2H, d, J 8.1), 7.88 (2H, d, J 7.1), 7.96 (2H, d, J 8.4), 8.02 (2H, d, 8.4), 8.25 (2H, d, J 5.9), 8.84 (2H, s).
- Step 1 ( ⁇ ) Methyl ⁇ (2R*, 4S*)-l-[(lS*)-4-methyl-l-(4-pyridin-2-ylphenyl)pentyl]-2-[4- (trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetate
- Step 2 ( ⁇ ) ⁇ (2R*, 45'*)-l-[(i5'*)-4-methyl-l-(4-pyridin-2-ylphenyl)pentyl]-2-[4-
- Step 1 ( ⁇ ) Methyl ⁇ (25',4 ⁇ )-l- ⁇ (5)-(2 ⁇ )-tetrahydrofuran-2-yl[4-(trifluoromethyl)phenyl]methyl ⁇ -2-[4- (trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetate and ( ⁇ ) methyl ⁇ (25',4 ⁇ )-l- ⁇ (5)-(25)-tetrahydrofuran-2- yl[4-(trifluoromethyl)phenyl]methyl ⁇ -2-[4-(trifluoromethyl)phenyl]piperidin-4-yl ⁇ acetate
- Step 2 ( ⁇ ) ⁇ (25',4 ⁇ )-l- ⁇ (5)-(2 ⁇ )-tetrahydrofuran-2-yl[4-(trifluoromethyl)phenyl]methyl ⁇ -2-[4-
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07733578A EP2001848B1 (en) | 2006-03-28 | 2007-03-27 | Piperidines and related compounds for the treatment of dementia |
JP2009502225A JP2009531407A (en) | 2006-03-28 | 2007-03-27 | Piperidine and related compounds for the treatment of dementia |
AU2007231164A AU2007231164A1 (en) | 2006-03-28 | 2007-03-27 | Piperidines and related compounds for the treatment of dementia |
AT07733578T ATE530525T1 (en) | 2006-03-28 | 2007-03-27 | PIPERIDINE AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA |
CA002647290A CA2647290A1 (en) | 2006-03-28 | 2007-03-27 | Piperidines and related compounds for the treatment of dementia |
US12/294,303 US8222418B2 (en) | 2006-03-28 | 2007-03-27 | Piperidines and related compounds for the treatment of dementia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0606015.6 | 2006-03-28 | ||
GBGB0606015.6A GB0606015D0 (en) | 2006-03-28 | 2006-03-28 | therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007110667A1 true WO2007110667A1 (en) | 2007-10-04 |
Family
ID=36384184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/050155 WO2007110667A1 (en) | 2006-03-28 | 2007-03-27 | Piperidines and related compounds for the treatment of dementia |
Country Status (8)
Country | Link |
---|---|
US (1) | US8222418B2 (en) |
EP (1) | EP2001848B1 (en) |
JP (1) | JP2009531407A (en) |
AT (1) | ATE530525T1 (en) |
AU (1) | AU2007231164A1 (en) |
CA (1) | CA2647290A1 (en) |
GB (1) | GB0606015D0 (en) |
WO (1) | WO2007110667A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
CN102249990A (en) * | 2011-06-08 | 2011-11-23 | 上海玉函化工有限公司 | Process for synthesizing 6-(trifluoromethyl)pyridine-3-carboxaldehyde |
US8367863B2 (en) | 2007-12-20 | 2013-02-05 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
US8420622B2 (en) | 2006-12-20 | 2013-04-16 | Merck, Sharp & Dohme, Corp. | Silylated piperidine derivatives |
US9771378B2 (en) | 2014-01-15 | 2017-09-26 | Denali Therapeutics, Inc. | Fused morpholinopyrimidines and methods of use thereof |
US9802927B2 (en) | 2015-06-10 | 2017-10-31 | Denali Therapeutics, Inc. | Oxadiazine compounds and methods of use thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007245435A1 (en) * | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Piperidines and related compounds for treatment of Alzheimer's disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020015941A1 (en) | 2000-03-22 | 2002-02-07 | The General Hospital Corporation | Method for treatment of neurodegenerative diseases |
WO2002092072A2 (en) | 2001-05-15 | 2002-11-21 | Nicox S.A. | Drugs for the treatment of the alzheimer disease |
WO2002100836A2 (en) | 2001-06-12 | 2002-12-19 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
WO2006043064A1 (en) | 2004-10-21 | 2006-04-27 | Merck Sharp & Dohme Limited | Piperidines and related compounds for treatment of alzheimer's disease |
-
2006
- 2006-03-28 GB GBGB0606015.6A patent/GB0606015D0/en not_active Ceased
-
2007
- 2007-03-27 AU AU2007231164A patent/AU2007231164A1/en not_active Abandoned
- 2007-03-27 CA CA002647290A patent/CA2647290A1/en not_active Abandoned
- 2007-03-27 US US12/294,303 patent/US8222418B2/en not_active Expired - Fee Related
- 2007-03-27 AT AT07733578T patent/ATE530525T1/en not_active IP Right Cessation
- 2007-03-27 JP JP2009502225A patent/JP2009531407A/en not_active Withdrawn
- 2007-03-27 WO PCT/GB2007/050155 patent/WO2007110667A1/en active Application Filing
- 2007-03-27 EP EP07733578A patent/EP2001848B1/en not_active Not-in-force
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020015941A1 (en) | 2000-03-22 | 2002-02-07 | The General Hospital Corporation | Method for treatment of neurodegenerative diseases |
WO2002092072A2 (en) | 2001-05-15 | 2002-11-21 | Nicox S.A. | Drugs for the treatment of the alzheimer disease |
WO2002100836A2 (en) | 2001-06-12 | 2002-12-19 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
WO2006043064A1 (en) | 2004-10-21 | 2006-04-27 | Merck Sharp & Dohme Limited | Piperidines and related compounds for treatment of alzheimer's disease |
Non-Patent Citations (4)
Title |
---|
JANTZEN ET AL., J. NEUROSCIENCE, vol. 22, 2002, pages 226 - 54 |
MORIHARA ET AL., J. NEUROCHEM., vol. 83, 2002, pages 1009 - 12 |
TAKAHASHI ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 18644 - 70 |
WEGGEN ET AL., NATURE, vol. 414, 2001, pages 212 - 16 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420622B2 (en) | 2006-12-20 | 2013-04-16 | Merck, Sharp & Dohme, Corp. | Silylated piperidine derivatives |
US8367863B2 (en) | 2007-12-20 | 2013-02-05 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
US8664249B2 (en) | 2007-12-20 | 2014-03-04 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
CN102249990A (en) * | 2011-06-08 | 2011-11-23 | 上海玉函化工有限公司 | Process for synthesizing 6-(trifluoromethyl)pyridine-3-carboxaldehyde |
US9771378B2 (en) | 2014-01-15 | 2017-09-26 | Denali Therapeutics, Inc. | Fused morpholinopyrimidines and methods of use thereof |
US9802927B2 (en) | 2015-06-10 | 2017-10-31 | Denali Therapeutics, Inc. | Oxadiazine compounds and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2647290A1 (en) | 2007-10-04 |
ATE530525T1 (en) | 2011-11-15 |
EP2001848B1 (en) | 2011-10-26 |
US20090239905A1 (en) | 2009-09-24 |
GB0606015D0 (en) | 2006-05-03 |
AU2007231164A1 (en) | 2007-10-04 |
US8222418B2 (en) | 2012-07-17 |
JP2009531407A (en) | 2009-09-03 |
EP2001848A1 (en) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7638629B2 (en) | Piperidines and related compounds for treatment of alzheimer's disease | |
US8389547B2 (en) | Piperidines and related compounds for the treatment of Alzheimer's disease | |
EP2001848B1 (en) | Piperidines and related compounds for the treatment of dementia | |
US7728022B2 (en) | (4, 5, 6, 7-tetrahydro-1-H-indol-7-yl) acetic acid derivatives for treatment of Alzheimer's disease | |
EP2007724B1 (en) | Piperidine derivatives for treatment of alzheimer's disease | |
EP2063710B1 (en) | Difluorinated piperidines for treatment of alzheimer's disease and related conditions | |
US8420622B2 (en) | Silylated piperidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07733578 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007231164 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007733578 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2647290 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009502225 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007231164 Country of ref document: AU Date of ref document: 20070327 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12294303 Country of ref document: US |